BACKGROUND: MDR1-associated P-glycoprotein-dependent multidrug resistance is a common cause of chemotherapy failure in patients with advanced ovarian cancer. Here, we describe a clinical method for simultaneously assessing the expression and function of the MDR1/Pgp in tumour cells from ascites of patients with malignant ovarian carcinoma. MATERIALS AND METHODS: Cells from ascites from 35 patients were collected. The expression and function of Pgp were detected by flow cytometry. For functional study, rhodamine 123 was used. RESULTS: Using the Pgp-specific UIC2 and MM6.15 antibodies, we demonstrated the presence of Pgp in 10-79% (38.9+/-20, 7; n=35) of the CA 125-positive cell subpopulations. The results of the functional assay showed strong correlation with the level of Pgp expression (r=0.976; p=3.2x10(-5)). CONCLUSION: Direct detection of the expression level and function of MDR1/Pgp in the ascites provide useful information for the more efficient treatment of malignant diseases by proper adjustment of the chemotherapeutic protocol.
BACKGROUND:MDR1-associated P-glycoprotein-dependent multidrug resistance is a common cause of chemotherapy failure in patients with advanced ovarian cancer. Here, we describe a clinical method for simultaneously assessing the expression and function of the MDR1/Pgp in tumour cells from ascites of patients with malignant ovarian carcinoma. MATERIALS AND METHODS: Cells from ascites from 35 patients were collected. The expression and function of Pgp were detected by flow cytometry. For functional study, rhodamine 123 was used. RESULTS: Using the Pgp-specific UIC2 and MM6.15 antibodies, we demonstrated the presence of Pgp in 10-79% (38.9+/-20, 7; n=35) of the CA 125-positive cell subpopulations. The results of the functional assay showed strong correlation with the level of Pgp expression (r=0.976; p=3.2x10(-5)). CONCLUSION: Direct detection of the expression level and function of MDR1/Pgp in the ascites provide useful information for the more efficient treatment of malignant diseases by proper adjustment of the chemotherapeutic protocol.
Authors: Jacqueline V Chapman; Valérie Gouazé-Andersson; Ramin Karimi; Maria C Messner; Myles C Cabot Journal: Exp Cell Res Date: 2011-03-21 Impact factor: 3.905